Revolutionizing Soft Tissue Repair
Nurami Medical Ltd. is a medical device company with a revolutionary, proprietary nanofiber and sealant technology focused on the soft tissue repair market – worth over $14 billion globally. With its ability to produce highly flexible, durable and multi-functional patches that seal undesired leakages and enhance tissue-regeneration, Nurami Medical is positioned at the forefront of next generation surgery. Nurami’s first product is a Dural substitute patch for neurosurgeries. Nurami’s ongoing R&D efforts are focused on developing new products to add to its pipeline as well as upgrading its core technology.
Present Status & Key Achievements
Nurami was established in 2014 and raised over $2M since then. Nurami is also supported financially by the Israeli Innovation Authority and by NGT3 Venture fund.
Major preclinical trials are completed and clinical trials are planned to start beginning of 2018.
Nurami seeks funding to complete clinical trials for CE and FDA approvals and to continue development of pipeline projects.
Our vision is to implement Nurami’s innovative nanofiber technology in a variety of soft tissue repair products and become a major player in next-generation surgery
Mr. Marksheid has over 25 years of senior and executive management experience, proven ability to lead business groups in a global environment and record of starting new businesses from scratch and leading them all the way into the marketplace
He is an expert in strategic planning, process implementation and program development with extensive experience in fundraising from angels, corporates, corporate funds, and the venture capital community, as well as raising non-diluting grants and debt instruments. Hannoch is the former founder and CEO of BioCEP, an innovative BioMedical company, and B-Control, a boutique consultancy for high-growth companies.
Mr. Marksheid holds a BA (Economics, Haifa University) and MBA (Strategic Management, West London Business School).
Ph.D., CTO and co-founder
Dr. Bahar is a multidisciplinary entrepreneur and scientist with over 15 years of experience in preclinical models of brain research, pharmacology and electrophysiology. He has close to 10 years of experience in the medical device industry with a focus on degradable implants and nanofibers. Prior to Nurami, he led the development of a novel hemostatic degradable implant. Dr Bahar received his Ph.D. in neurobiology from the Weizmann Institute and won a NARSAD Young Investigator Award (2008).
M.Sc., CTO, co-founder and board member
Mrs. Nseir is a biomedical entrepreneur. Previously, she led the development of a bone graft based on nanofibers at the Technion and Bonus BioGroup. Before that, Mrs. Nseir worked as a R&D engineer at the Technion in cooperation with BiolineRX, developing a novel nanofiber hemostatic device. Ms. Nseir brings extensive experience in developing nanofiber based medical devices, biomaterials and nanotechnology. Holds a B.Sc. and M.Sc. in biomedical engineering and regenerative medicine (Technion).
Mrs. Nseir co-founded the Arab Women in Science non-profit forum (AWSc), which advance and encourage Arab women to be involved in entrepreneurship in science and technology. She is an active volunteer in social ventures that promote entrepreneurship among young students from the periphery of Israel.
Harel Kasuto, Ph.D.
Dr. Kasuto is a scientist with over 10 years of diverse experience in R&D in the biotechnology industry, among which in molecular biology, immunotherapy, cell therapy and electrospinning. Dr. Kasuto received his Ph.D. in biology from the Hebrew University.
Product and QA Engineer
M.Sc., Product and QA Engineer
Mrs Omar holds a B.Sc. in Food and Biotechnology Engineering from the Technion (Israel Institute of Technology) where she specialized in Quality Engineering; and M.Sc. (MED) with distinction in Biomedical Engineering from the University of Cape Town, where she specialized in the development of bio-material scaffolds and bio-mimetic matrices for tissue engineering and regenerative medicine applications.
In addition to her research activities during her graduate studies; Rodaina has supported several research projects for both undergraduate and postgraduate students where she gained advanced experience in the electrospinning technology. She has also given a Food Analysis course for undergraduate students at Sakhnin Academic College and monitored and supported several academic & career orientation projects for both high and elementary school students.
Mrs. Omar has joined Nurami Medical as a Product and QA Engineer in 2017, and since then she is responsible for product development and managing the company’s quality system and R&D department.
Malca Chen-Zion, Ph.D.
Dr. Chen-Zion has over two decades of experience in the fields of regulatory affairs, pre-clinical research and clinical trials of medical devices. In her many years of activity, Dr. Chen-Zion has held various management positions. Since 2004 she has been consulting various companies in diverse fields, including cardiology, ophthalmology, orthopedics, dentistry, neurology, gastroenterology, and others.
From 2011 to 2015 Dr. Chen-Zion held teaching positions for graduate students at Ort Braude College in the department of Biotechnology Engineering to second degree students. She earned a Ph.D. in Biology with highest distinction from Bar-Ilan University, Israel.
M.A., Chairman of the board
Former CEO of Elron Electronic Industries (Nasdaq ELRNF &TASE ). Former Chairman, and a board member of Given Imaging (NASDAQ and TASE). Currently Chairman and a board member of several Israeli technology companies (private and public), mainly in the medical device sector.
M.Sc., Board member
CEO and managing partner of NGT3VC Venture Fund, Nazareth, Israel. Mr. Gendler was the CEO and director of Beta-O2 for 8 years, leading the company to be one of the world leaders in the field. Between 1995 to 2006 he served as CEO of the Technion Entrepreneurial Incubator (Haifa), where he led the establishment of more than 40 companies, such as Prolor Biotech (sold to Opko for $480M in 2014), Mazor Robotics (NASDAQ: MZOR), ReWalk (NASDAQ: RWLK). Mr. Gendler earned his M.Sc. in Material Engineering from the Technion.
Scientific Advisory Board
Prof. Andrew Kaye, MD
Professor Kaye is Professor of Surgery, Head of the Department of Surgery (RMH) at The University of Melbourne and Head of the Department of Neurosurgery at The Royal Melbourne Hospital. He is also the President of the Asian Australasian Society of Neurological Surgeons. Prof. Kaye is the foundation Editor-in-Chief of the Journal of Clinical Neuroscience. Has authored and co-authored over 150 journal articles and book chapters, as well as five books including the co-author of “Brain Tumors”, a text recognized as being the definitive work on the subject.
Prof. Issam Awad, MD
An internationally recognized leader in neurosurgery. He is the director of the neurovascular division at Chicago university hospital. He has served as President of the Congress of Neurological Surgeons and published over 250 papers. He also led several clinical trials on minimally invasive neurosurgical techniques.
Sagi Harnof, MD
Dr. Harnof is a senior neurosurgeon and the Head of the Neurosurgery Department at Rabin Medical Center, Petach Tikwa, the 3rd largest hospital in Israel. He specializes in cerebal-vasculature and in brain tumors surgeries. Dr. Harnof received his M.D. from Tel-Aviv University. Dr. Harnof is involved in many pre-clinical and clinical studies in several fields. He is involved in various research projects in different research centers in the EU and the US.
Prof. Eyal Zussman, Ph.D
Prof. Zussman has been at the Department of Mechanical Engineering, Technion – Israel Institute of Technology since 1994. He received his doctor’s degree in mechanical engineering from the Technion. His research includes polymer processing, electrospinning, and materials characterization. Prof. Zussman has been active in biomedical applications aiming at developing dental membranes, biodegradable extra cellular matrix (ECM), and drug delivery systems all based on electrospun fibers. He has published more than 100 journal publications and holds more than 10 patents.
Prof. Michael Schulder, M.D.
Prof. Schulder serves as the Vice Chairman of the Department of Neurosurgery and Director of the Brain Tumor Center at the Hofstra Northwell School of Medicine, Manhasset, NY.
Dr. Schulder is named as one of the top doctors in the New York metropolitan area annually for over a decade. In addition, he is an internationally recognized expert in the use of stereotactic methods to treat patients with brain tumors.
He has authored more than 70 peer-reviewed articles, 31 abstracts, 17 book chapters and over 200 presentations at national and international meetings. He has received the Leonard Tow Award for Humanism in Medicine and has been elected to the Gold Humanism Honors Society.